Sponsor
Maria Elvira Salazar
Representative · R-FL
Representative · R-FL
The bill strengthens domestic medical and defense supply-chain resilience and increases oversight and regulatory clarity, but does so at the risk of higher public and patient costs, expanded federal procurement authority, potential market concentration, and possible disruption to existing contracts and competition.
Hospitals and patients who depend on drugs, devices, and biologics would face fewer supply disruptions during emergencies because the bill requires clearer federal planning and coordination of medical supplies.
U.S. manufacturers and suppliers (including small businesses) may receive federal payments to strengthen domestic supply chains, improving production resilience for defense-critical goods and reducing reliance on foreign suppliers.
Congress and stakeholders get clearer oversight and regulatory certainty via required strategy and annual progress reports through 2029 and by mandating clear definitions within 90 days, improving transparency, accountability, and planning/compliance for governments and businesses.
Taxpayers and patients may face higher costs because securing supply chains and subsidizing domestic producers can raise production costs, increase public spending, and possibly lead to higher prices for drugs and devices.
Expanded executive authority over procurement and use of DPA-type powers could impose administrative burdens and federal intervention on hospitals and state governments.
Redirecting production or redirecting suppliers under emergency authorities could disrupt existing commercial contracts and supply relationships, harming domestic and smaller suppliers.
Based on analysis of 3 sections of legislative text.
Directs the President to produce a DPA-based strategy to secure medical supply chains, authorizes payments to U.S. entities to strengthen supply chains, and requires regulatory definitions within set deadlines.
Official title: To amend the Defense Production Act of 1950 to ensure the supply of certain medical materials essential to national defense, and for other purposes.
Introduced March 3, 2026 by Maria Elvira Salazar · Last progress March 3, 2026
Requires the President to use Defense Production Act (DPA) authorities to secure U.S. medical supply chains and to produce a national strategy for doing so within set deadlines. Creates a temporary payment authority to pay eligible U.S.-organized entities to strengthen supply chains, and directs the executive branch to issue definitions and regulations for “supply chain” and “supply chain activities.”